SS
Stein Steven H Directeur Médical
Other M
Insider track record Executive Across 14 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Browse the complete record of transactions filed by Stein Steven H, Directeur Médical. Director active across 1 company, notably INCYTE CORP. Cumulatively, 24 filings have been recorded. Split: 0 buy · 5 sells. Total volume traded: €5.3m. History available since 28 June 2021. The latest transaction was disclosed on 2 July 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Declarations 24 total
● CMO & Head of Late-Stage Dev. · Executives · 2 Jul 2026 · INCYTE CORP 2,177 shares @ US$116.86 Common Stock SEC:0001673776-26-000015:0
◆ EVP & Chief Medical Officer · Executives · 1 Apr 2025 · INCYTE CORP 37,198 shares 0Common Stock SEC:0001628280-25-016576:0
▼ EVP & Chief Medical Officer · Executives · 21 Jan 2025 · INCYTE CORP 12,352 shares @ US$72.69 7.8% of flow Common Stock SEC:0000879169-25-000032:0
● EVP & Chief Medical Officer · Executives · 15 Jan 2025 · INCYTE CORP 10,692 shares @ US$72.46 6.8% of flow Common Stock SEC:0000879169-25-000016:0
▼ EVP & Chief Medical Officer · Executives · 12 Aug 2024 · INCYTE CORP 11,608 shares @ US$60.63 5.8% of flow Common Stock SEC:0000879169-24-000151:0
◆ EVP & Chief Medical Officer · Executives · 15 Jul 2024 · INCYTE CORP 13,895 shares 0Common Stock SEC:0000879169-24-000139:0
● EVP & Chief Medical Officer · Executives · 2 Jul 2024 · INCYTE CORP 8,316 shares @ US$59.02 4.1% of flow Common Stock SEC:0000879169-24-000112:0
◆ EVP & Chief Medical Officer · Executives · 14 Feb 2024 · INCYTE CORP 7,377 shares 0Common Stock SEC:0000879169-24-000058:0
▼ EVP & Chief Medical Officer · Executives · 3 Jan 2024 · INCYTE CORP 7,365 shares @ US$65.51 4.0% of flow Common Stock SEC:0000879169-24-000008:0
▼ EVP & Chief Medical Officer · Executives · 1 Aug 2023 · INCYTE CORP 21,511 shares @ US$63.28 11.2% of flow Common Stock SEC:0001209191-23-044393:0
◆ EVP & Chief Medical Officer · Executives · 14 Jul 2023 · INCYTE CORP 13,535 shares 0Common Stock SEC:0001209191-23-042550:0
● EVP & Chief Medical Officer · Executives · 3 Jul 2023 · INCYTE CORP 8,442 shares @ US$62.08 4.4% of flow Common Stock SEC:0001209191-23-041511:0
◆ EVP & Chief Medical Officer · Executives · 20 Jan 2023 · INCYTE CORP 4,980 shares 0Common Stock SEC:0001209191-23-004568:0
▼ EVP & Chief Medical Officer · Executives · 4 Jan 2023 · INCYTE CORP 28,399 shares @ US$79.78 19.5% of flow Common Stock SEC:0001209191-23-002318:0
◆ EVP & Chief Medical Officer · Executives · 2 Jul 2022 · INCYTE CORP 18,941 shares 0Common Stock SEC:0001209191-22-041082:0
● EVP & Chief Medical Officer · Executives · 28 Jun 2022 · INCYTE CORP 11,488 shares @ US$75.63 0.0043% mcap 20.7% of flow Common Stock SEC:0001209191-22-039904:0
◆ EVP & Chief Medical Officer · Executives · 1 Jan 2022 · INCYTE CORP 28,926 shares 0Common Stock SEC:0001209191-22-001670
◆ EVP & Chief Medical Officer · Executives · 1 Jan 2022 · INCYTE CORP 28,926 shares 0Common Stock SEC:0001209191-22-001670:0
◆ EVP & Chief Medical Officer · Executives · 19 Nov 2021 · INCYTE CORP 379 shares 0Common Stock SEC:0001209191-21-066430:0
◆ EVP & Chief Medical Officer · Executives · 19 Nov 2021 · INCYTE CORP 379 shares 0Common Stock SEC:0001209191-21-066430
◆ EVP & Chief Medical Officer · Executives · 2 Jul 2021 · INCYTE CORP 7,853 shares 0Common Stock SEC:0001209191-21-045888:0
◆ EVP & Chief Medical Officer · Executives · 2 Jul 2021 · INCYTE CORP 7,853 shares 0Common Stock SEC:0001209191-21-045888
● EVP & Chief Medical Officer · Executives · 28 Jun 2021 · INCYTE CORP 22,079 shares @ US$85.61 14.4% of flow Common Stock SEC:0001209191-21-043978
● EVP & Chief Medical Officer · Executives · 28 Jun 2021 · INCYTE CORP 22,079 shares @ US$85.61 0.0083% mcap 39.7% of flow Common Stock SEC:0001209191-21-043978:0
About Stein Steven H Stein Steven H serves as Executive Vice President and Chief Medical Officer at Incyte Corp. In this role, he is responsible for the company's medical strategy and research initiatives. His expertise in biotechnology enables him to lead teams in developing new treatments. He plays a crucial role in guiding Incyte's research and development efforts.